Here are the DEF 14A proxy statements from Arbutus Biopharma Corporation (ABUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ABUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABUS filings page.
Arbutus Biopharma Corporation is asking shareholders to vote at its 2026 Annual General and Special Meeting on May 26, 2026 in Vancouver, BC. Holders of 196,939,679 common shares outstanding as of March 30, 2026 may vote.
Shareholders will elect five directors, consider a new 2026 Omnibus Share and Incentive Plan authorizing up to 16,300,000 common shares for equity awards, hold an advisory “say‑on‑pay” vote on named executive officer compensation, and approve the appointment of EY as independent registered public accounting firm for 2026. Materials are delivered primarily online, with voting available by mail, phone, Internet, or in person.